Tobramycin inhalations in therapy of chronic infection Pseudomonas aeruginosa in cystic fibrosis

Амелина, Array Л.; Красовский, А.

doi:10.18093/0869-0189-2013-0-4-109-114

Cited by 2 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Tobramycin, intended for intravenous intake, before the appearance of the inhalation form, was diluted with a physiological solution and used in inhalations through a nebulizer 28 . A specific formula of tobramycin for inhalation was developed in the 1980s 15 .…”

Section: Tobramycinmentioning

confidence: 99%

“…Currently, in the world 3 drugs of tobramycin especially designed for inhalations are widely used: tobramycin -a solution for inhalations «Bramitob», «Tobi» and tobramycin in the form of powder -«Tobi Podhaler». All these drugs are intended for a basic therapy in adults and children with CF and a confirmed infection with P. aeruginosa 28,29 .…”

Section: Tobramycinmentioning

confidence: 99%

“…Unlike to parenteral, inhalational forms of tobramycin do not have nephrotoxicity or ototoxicity 28 . This is due to the fact that the inhalational form provides a low concentration of tobramycin in blood plasma after inhalation (<1 mg/L), which is much lower than the concentration that causes systemic toxic effect (> 10-12 mg/L) 28 .…”

Section: Tobramycinmentioning

confidence: 99%

See 2 more Smart Citations

Perspectives of the Inhaled Antibiotics Usage in Pediatrics

Boyarchuk¹,

KRYTSKA²,

CHORNOMYDZ³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

Perspectives d'utilisation des antibiotiques inhalés en pédiatrie La thérapie antibactérienne chez les enfants reste un problème complexe et non résolu de la médecine. Malgré le fait que les antibiotiques forment l'un des groupes de remèdes le plus répandu, chaque année de plus en plus de bactéries deviennent résistantes à ces médicaments. Un petit nombre de nouveaux antibactériens introduits en pratique reste également un moment négatif. Ce problème devient particulièrement actuel lors de maladies respiratoires. Cela est due au fait que les antibiotiques systémiques pénètrent assez mal dans le tissu pulmonaire et ne créent pas de hautes concentrations au site de l'inflammation. Avec l'accroissement du nombre de dosages des antibactériens systémiques augmentent aussi leurs effets toxiques sur l'organisme du patient. Par conséquent, l'utilisation de ces médicaments par voie inhalée est de perspective et réduit le risque de développement

show abstract

Section: Tobramycinmentioning

confidence: 99%

Section: Tobramycinmentioning

confidence: 99%

See 1 more Smart Citation

Perspectives of the Inhaled Antibiotics Usage in Pediatrics

Boyarchuk¹,

KRYTSKA²,

CHORNOMYDZ³

et al. 2018

Arch Balk Med Union

View full text Add to dashboard Cite

show abstract

Clinical cases of Pseudomonas aeruginosa eradication in patients with cystic fibrosis

Zhekaite

Kondratyeva

2022

Pulʹmonologiâ (Mosk.)

View full text Add to dashboard Cite

Pseudomonas aeruginosa is the most common highly pathogenic flora in patients with cystic fibrosis. It is associated with severe lung damage and affects life expectancy. According to the register of patients with cystic fibrosis in the Russian Federation (2019), the incidence of P. aeruginosa pulmonary infection among them is 34.3%. Inhaled tobramycin is the drug of choice for the eradication of P. aeruginosa in patients with cystic fibrosis according to European and Russian recommendations. Clinical studies showed that Bramitob is highly effective against P. aeruginosa infection in patients with cystic fibrosis.The aim of the study: to demonstrate the effectiveness and safety of eradication therapy with inhaled tobramycin in several clinical cases of children with cystic fibrosis.Methods. The article analyzes 6 clinical cases of effective eradication of P. aeruginosa in patients with cystic fibrosis, including 1 clinical case that involved a new approach to assessing the resistance of P. aeruginosa. Positive culture of P. aeruginosa was confirmed in all patients in specialized laboratories (State Budgetary Healthcare Institution “Morozov Children’s City Clinical Hospital of the Department of Health of the City of Moscow”, Federal State Budgetary Institution “N.F.Gamaleya National Research Center for Epidemiology and Microbiology”, Ministry of Health of the Russian Federation). All patients received inhaled tobramycin 300 mg 2 times a day for 1 – 3 courses (a course of 28 days of inhalations/28 days – a break).Results. All children tolerated tobramycin well, and two of them were younger than 6 years old. The effectiveness of eradication was confirmed by negative cultures of P. aeruginosa during 1-year follow-up that included quarterly microbiological control. The clinical case that involved assessment of resistance to inhaled tobramycin is especially important because of polyresistance of the pathogen.Conclusion. The presented clinical cases of eradication of P. aeruginosa with the use of tobramycin confirm its clinical efficacy and wider application possibilities.

show abstract

Tobramycin inhalations in therapy of chronic infection Pseudomonas aeruginosa in cystic fibrosis

Abstract: Информация об авторахАмелина Елена Львовна -к. м. н., зав. лабораторией муковисцидо за ФГБУ "НИИ пульмонологии" ФМБА России; тел.:

Cited by 2 publications

References 26 publications

Perspectives of the Inhaled Antibiotics Usage in Pediatrics

Perspectives of the Inhaled Antibiotics Usage in Pediatrics

Clinical cases of Pseudomonas aeruginosa eradication in patients with cystic fibrosis

Contact Info

Product

Resources

About